TNNI3 and COVID-19: Patients with COVID-19 and elevated myoglobin levels are at significantly high risk of severe disease and mortality, the presence of elevated myoglobin being more common than elevated cTnI in patients with severe COVID-19 [37.7 (23.3–52.1%) vs. 30.7% (24.7–37.1%)] and preferred as a cardiac biomarker in case of severe patients [13].